Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.23), $0.11 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $10.73 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.